| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
40,010,000 |
| Market
Cap: |
490.92(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.86 - $18.69 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 15.9 |
| Insider 3/6 Months : 16.5 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Y-mAbs Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Co.'s approved drug DANYELZA® (naxitamab-gqgk) was approved by the U.S. Food and Drug Administration for the treatment, in combination with Granulocyte-Macrophage Colony-Stimulating Factor of pediatric patients one year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
371,682 |
558,056 |
762,731 |
| Total Buy Value |
$0 |
$2,488,242 |
$3,530,830 |
$5,499,522 |
| Total People Bought |
0 |
2 |
2 |
3 |
| Total Buy Transactions |
0 |
10 |
14 |
17 |
| Total Shares Sold |
39,644 |
189,644 |
339,644 |
339,644 |
| Total Sell Value |
$515,799 |
$1,516,799 |
$2,312,182 |
$2,312,182 |
| Total People Sold |
3 |
3 |
3 |
3 |
| Total Sell Transactions |
5 |
8 |
10 |
10 |
| End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kruse Bo |
EVP, CFO, Secretary & Treas. |
• – – |
2021-11-04 |
4 |
AS |
$27.54 |
$110,160 |
D/D |
(4,000) |
209,077 |
|
-49% |
|
| Kruse Bo |
EVP, CFO, Secretary & Treas. |
• – – |
2021-10-22 |
4 |
AS |
$25.94 |
$103,760 |
D/D |
(4,000) |
213,077 |
|
-69% |
|
| Gad Thomas |
See remarks |
• • – |
2021-10-15 |
4 |
AS |
$27.20 |
$108,799 |
I/I |
(4,000) |
1,492,927 |
|
-66% |
|
| Kruse Bo |
EVP, CFO, Secretary & Treas. |
• – – |
2021-10-04 |
4 |
AS |
$28.78 |
$115,120 |
D/D |
(4,000) |
217,077 |
|
-72% |
|
| Gad Thomas |
See remarks |
• • – |
2021-09-30 |
4 |
AS |
$28.26 |
$113,054 |
I/I |
(4,000) |
1,496,927 |
|
-77% |
|
| Kruse Bo |
EVP, CFO, Secretary & Treas. |
• – – |
2021-09-22 |
4 |
AS |
$30.82 |
$123,280 |
D/D |
(4,000) |
221,077 |
|
-71% |
|
| Gad Thomas |
See remarks |
• • – |
2021-09-15 |
4 |
AS |
$33.64 |
$134,579 |
I/I |
(4,000) |
1,500,927 |
|
-71% |
|
| Kruse Bo |
EVP, CFO, Secretary & Treas. |
• – – |
2021-09-07 |
4 |
AS |
$32.03 |
$128,120 |
D/D |
(4,000) |
225,077 |
|
-65% |
|
| Gad Thomas |
See remarks |
• • – |
2021-09-07 |
4 |
OE |
$2.00 |
$100,000 |
D/D |
50,000 |
50,000 |
|
- |
|
| Gad Thomas |
See remarks |
• • – |
2021-09-02 |
4 |
S |
$33.18 |
$1,658,915 |
I/I |
(50,000) |
1,504,927 |
|
62% |
|
| Kruse Bo |
EVP, CFO, Secretary & Treas. |
• – – |
2021-08-23 |
4 |
AS |
$28.60 |
$114,400 |
D/D |
(4,000) |
229,077 |
|
-40% |
|
| Gad Thomas |
See remarks |
• • – |
2021-08-17 |
4 |
AS |
$28.96 |
$51,527 |
I/I |
(1,779) |
1,554,927 |
|
-41% |
|
| Gad Thomas |
See remarks |
• • – |
2021-08-16 |
4 |
AS |
$29.14 |
$765,071 |
I/I |
(26,111) |
1,556,706 |
|
-41% |
|
| Gad Thomas |
See remarks |
• • – |
2021-08-13 |
4 |
AS |
$31.01 |
$34,426 |
I/I |
(1,110) |
1,582,817 |
|
-39% |
|
| Rajah Vignesh |
SVP & CMO |
• – – |
2021-08-12 |
4 |
B |
$29.95 |
$41,147 |
I/I |
1,374 |
3,071 |
1.99 |
-43% |
|
| Kruse Bo |
EVP, CFO, Secretary & Treas. |
• – – |
2021-08-04 |
4 |
AS |
$33.72 |
$134,880 |
D/D |
(4,000) |
233,077 |
|
-55% |
|
| Gad Thomas |
See remarks |
• • – |
2021-08-03 |
4 |
AS |
$33.73 |
$134,927 |
I/I |
(4,000) |
1,583,927 |
|
-52% |
|
| Kruse Bo |
EVP, CFO, Secretary & Treas. |
• – – |
2021-07-22 |
4 |
AS |
$34.50 |
$138,000 |
D/D |
(4,000) |
237,077 |
|
-51% |
|
| Gad Thomas |
See remarks |
• • – |
2021-07-20 |
4 |
AS |
$32.47 |
$129,875 |
I/I |
(4,000) |
1,587,927 |
|
-46% |
|
| Gad Thomas |
See remarks |
• • – |
2021-07-07 |
4 |
AS |
$31.87 |
$127,465 |
I/I |
(4,000) |
1,591,927 |
|
-31% |
|
| Kruse Bo |
EVP, CFO, Secretary & Treas. |
• – – |
2021-07-06 |
4 |
AS |
$34.15 |
$136,600 |
D/D |
(4,000) |
241,077 |
|
-33% |
|
| Gad Thomas |
See remarks |
• • – |
2021-06-30 |
4 |
AS |
$33.86 |
$135,446 |
I/I |
(4,000) |
1,595,927 |
|
-34% |
|
| Kruse Bo |
EVP, CFO, Secretary & Treas. |
• – – |
2021-06-22 |
4 |
AS |
$36.17 |
$144,680 |
D/D |
(4,000) |
245,077 |
|
-24% |
|
| Gad Thomas |
See remarks |
• • – |
2021-06-14 |
4 |
AS |
$35.80 |
$143,217 |
I/I |
(4,000) |
1,599,927 |
|
-28% |
|
| Wedell-Wedellsborg Johan |
Director |
– • – |
2021-06-10 |
4 |
S |
$36.15 |
$405,971 |
I/I |
(11,229) |
4,178,465 |
|
29% |
|
249 Records found
|
|
Page 4 of 10 |
|
|
0.13 (1.07%) 
